Skip Navigation


Glycobiology Advance Access originally published online on May 1, 2008
Glycobiology 2008 18(7):559-565; doi:10.1093/glycob/cwn038
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
18/7/559    most recent
cwn038v3
cwn038v2
cwn038v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sprott, G D.
Right arrow Articles by Whitfield, D. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sprott, G D.
Right arrow Articles by Whitfield, D. M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2008.

Adjuvant potential of archaeal synthetic glycolipid mimetics critically depends on the glyco head group structure

G Dennis Sprott1,3, Chantal J Dicaire3, Jean-Philippe Côté2,3 and Dennis M Whitfield3

3 National Research Council of Canada, Institute for Biological Sciences, 100 Sussex Drive, Ottawa, Ontario K1A 0R6, Canada

1 To whom correspondence should be addressed: Tel: +1-613-998-7891; Fax: +1-613-952-9092; e-mail: dennis.sprott{at}nrc-cnrc.gc.ca

Received on February 28, 2008; revised on April 4, 2008; accepted on April 28, 2008

Subunit vaccines capable of providing protective immunity against the intracellular pathogens and cancers that kill millions of people annually require an adjuvant capable of directing a sufficiently potent cytotoxic T lymphocyte response to purified antigens, without toxicity issues. Archaeosome lipid vesicles, prepared from isoprenoid lipids extracted from archaea, are one such adjuvant in development. Here, the stability of an archaeal core lipid 2,3-di-O-phytanyl-sn-glycerol (archaeol) is used to advantage to synthesize a series of disaccharide archaeols and show that subtle variations in the carbohydrate head group alters the type and potency of immune responses mounted in a mammal. Critically, a glycosylarchaeol was required to elicit high cytotoxic CD8+ T cell activity, with highest responses to the antigen entrapped in archaeosomes containing disaccharides of glucose in β- or {alpha}1–6 linkage (β-gentiobiose, β-isomaltose), or of β-lactose. This first study on synthetic archaeal lipid adjuvants reveals potential for this class of regulatory friendly, easily scalable, inexpensive, and potent glyco-adjuvant.

Key words: adjuvant / archaea / disaccharides / glycosylarchaeols / synthesis

2 Present address: Université de Montréal, Faculté de Médecine Vétérinaire, St. Hyacinthe, 3200 Sicotte, Québec J2S 7C6, Canada.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GlycobiologyHome page
G D. Sprott, J.-P. Cote, and H. C Jarrell
Glycosidase-induced fusion of isoprenoid gentiobiosyl lipid membranes at acidic pH
Glycobiology, March 1, 2009; 19(3): 267 - 276.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.